SERPING1 and hereditary angioedema: In summary of our results, we can conclude that treatment with the lowest effective (33–220 mg/day) doses of danazol-an agent used for the treatment of C1-INH-HAE in clinical practice for nearly four decades-did not induce haematological abnormalities that would require the discontinuation of dosing, even after long-term use.